The effect of t(11;14) on the efficacy of venetoclax in myeloma: data from a retrospective analysis

Harsh Parmar, MD, Hackensack University Medical Center, Hackensack, NJ, comments on the role of venetoclax in the treatment of multiple myeloma (MM), highlighting the effect of the t(11;14) translocation on the efficacy of this agent. Dr Parmar notes that patients harboring the t(11;14) translocation exhibit a higher response rate and prolonged progression-free survival (PFS) compared to those without it, emphasizing the importance of identifying this subgroup to inform treatment selection. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Видео The effect of t(11;14) on the efficacy of venetoclax in myeloma: data from a retrospective analysis канала VJHemOnc – Video Journal of Hematology & HemOnc